Apogee Therapeutics to Participate in Upcoming November Investor Conferences
04 nov. 2024 07h30 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
24 oct. 2024 08h00 HE
|
Apogee Therapeutics
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved...
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
16 oct. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
12 sept. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
09 sept. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
19 août 2024 07h00 HE
|
Apogee Therapeutics, LLC
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in...
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
28 mai 2024 07h30 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
23 mai 2024 07h30 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
15 mai 2024 16h01 HE
|
Apogee Therapeutics, LLC
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week...
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
13 mai 2024 07h00 HE
|
Apogee Therapeutics, LLC
Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week...